Mirzotamab clezutoclax
Gecertificeerd

Mirzotamab clezutoclax

Catalog #: HY-P99741
Maat: 1 Each

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100

Technische Specificaties

Description

Mirzotamab clezutoclax (ABBV-155) is a first-in-class antibody-drug conjugate (ADC) with three components: an anti-B7-H3 monoclonal antibody, and BCL2L1 (BCL-XL) inhibitor Clezutoclaxum. Mirzotamab clezutoclax can be used for the study of relapsed and/or refractory (R/R) solid tumors[1].

CAS Number

2229859-12-3

Product Name Alternative

ABBV-155

UNSPSC

12352100

Target

Antibody-Drug Conjugates (ADCs) ; Bcl-2 Family; CD276/B7-H3

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

[Mirzotamabclezutoclax]

References & Citations

[1]Tolcher A W, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. 2021.

Shipping Conditions

Room temperature

Product MSDS

http://file.medchemexpress.com/batch_PDF/HY-P99741/

Scientific Category

Inhibitory Antibodies

Clinical Information

No Development Reported

Isoform

Bcl-xL

Beschrijving

Mirzotamab clezutoclax (ABBV-155) is a first-in-class antibody-drug conjugate (ADC) with three components: an anti-B7-H3 monoclonal antibody, and BCL2L1 (BCL-XL

Specificaties

ProductnaamMirzotamab clezutoclax
Categorie
Beschikbare grootte1 Each
CatalogusnummerHY-P99741